Dr. Wolfgang Knirsch
Dr. Wolfgang Knirsch (CEO)
CEO of Vita 34 AG
Dr. Wolfgang Knirsch, born in 1960, has been a member of the board of Vita 34 AG since June 2016 and was appointed CEO of Vita 34 AG in June 2017.
After he received his PhD in inorganic chemistry by RWTH Aachen, Dr. Wolfgang Knirsch made a shift from institutional research to the pharmaceutical industry in 1992. He started his career in the sales and marketing division of Hoechst AG. Later, he was in charge of the product management of internationally relevant ethical preparations of the successor company Aventis Pharma GmbH. When he went to work for Merck KGaA, he became responsible for new business and national marketing of the company’s most important product sector.
In 2005, Dr. Knirsch took over the management of the operational and strategic marketing of Biotest AG. After the successful restructuring and reorganization of the division, he made a shift to the international line of business in 2011. In his position as Vice President of International Business, he successfully advanced the strategically relevant department worth several hundred millions of Euros involving distribution partners worldwide.
Falk Neukirch (CFO)
CFO of Vita 34 AG
Falk Neukirch, born in 1971, was appointed CFO of Vita 34 in October 2015.
He successfully completed his studies of Business at the Technical University Dresden with the degree “Diplom-Kaufmann” [MBA]. Following his studies he worked for a large auditing firm for several years and assumed various management functions in the area of finance.
From 2007–2014 Mr. Neukirch was the Director of Controlling at the publicly traded First Sensor AG, and in this time accompanied several company acquisitions. His last position was as Finance Director and an authorized officer of BGH Edelstahlwerke GmbH.
Mr. Falk Neukirch has extensive knowledge in international accounting (IFRS) prescribed for publicly traded companies, as well as experience in company acquisitions and their integration.
Member of management board of Vita 34 AG
Alexander Starke, born in 1974, has been a member of the management board of Vita 34 AG since June 2017.
As a graduated lawyer, he has been working in the field of bank and capital market law since 2010. Until 2015, Starke managed the department of bank and capital market law of an economically oriented, medium-sized law firm in Erlangen, where he was responsible among other things for the strategic counseling of companies managed by their owners. In 2015, he opened his own law firm specializing in bank and capital market law and is admitted to work as mediator and referee (Conciliation and Arbitration Rules for Construction Disputes – SOBau) in parallel since then. Since May 2012, Starke has been a member of the supervisory board of Vita 34 AG. He was appointed the vice president in July 2015 and delegated to the management board of Vita 34 AG in June 2017.
In addition to passing the resolution of amending the articles of association as to reduce the number of members of the supervisory board from six to four, two new members were elected to the supervisory board at the general shareholders’ meeting on June 28, 2017. The new members of the supervisory board are Frank Köhler and Steffen Richtscheid.
At the following meeting, the supervisory board elected Frank Köhler the new chairman. He took this office in place of Dr. Hans-Georg Giering, whose term of office – like that of Alexander Starke and Dr. Holger Födisch – ended that day. Gerrit Witschaß remains the vice chairwoman and Dr. med. Mariola Söhngen remains the fourth member of the supervisory board.
With effect from the end of the general shareholders’ meeting on June 28, 2017, Artur Isaev resigned from the supervisory board of Vita 34 AG.